\n \n \n “. concat(self. i18n. t(‘search. voice. recognition_retry’), “\n
Expanding biopharmaceutical processing tube manufacturing capabilities with state-of-the-art infrastructure will increase visitor numbers
WILMINGTON, Wash. , May 31, 2022 /PRNewswire-PRWeb/ — DuPont (NYSE: DD) today announced the opening of its new DuPont™ Liveo™ Healthcare production facility in Cooper River, South Carolina, to better serve its consumers worldwide. world.
The site, in Berkeley County, will operate on the same quality criteria as DuPont’s healthcare industries materials site, the company’s long-standing biopharmaceutical production facility in Hemlock, Michigan. The Cooper River site will bring more extrusion capacity online over the next two years to serve strategic short-term consumers and expand its Liveo™ Healthcare visitor base with an additional medium-term offering.
“Investing in biopharmaceutical production at Cooper River is a key step in our expansion strategy; supports our customers’ expansion and contributes to continuity,” said Eugenio Toccalino, global chief commercial officer, DuPont Healthcare.
DuPont™ Liveo™ Healthcare is also expanding its production footprint regionally for local consumers, which will help reduce source tension and allow consumers to expand into their respective markets. In the current part of 2022, the company plans to increase the biopharmaceutical capacity of silicone tubes in China. to serve fast-growing consumers in the region.
“Thanks to a strong and close collaboration between our DuPont team and our subcontractor partners, the structure of the new Cooper River site was completed in 18 months, without a single safety incident,” said Bill Alexander, Cooper River unit and site manager for DuPont™. . Liveo™ and MOLYKOTE® facilities”. The site has enabled the creation of 25 positions in the start-up, and another 25 positions are expected to be created as we ramp up our operations over the next two years,” Alexander added.
“For more than fourteen years, DuPont Cooper River has continued to diversify and reinvest in new products that ensure the viability of this Berkeley County facility. Innovation in life sciences and biotechnology is a developing sector with an annual economic impact of $11 billion and more than 40,000 jobs in the state of South Carolina. We thank DuPont for its commitment to this network and for creating more high-paying jobs for the local workforce,” said Kristen O. Lanier, Berkeley County Director of Economic Development.
In 2021, DuPont Cooper River expanded to include the manufacture of DuPont™ MOLYKOTE® specialty lubricants.
As a trusted partner in the healthcare transformation industry, DuPont has developed an industry-leading position by leveraging more than seven decades of core functions serving the highly regulated biopharmaceutical market. its consumers through high-quality, high-performance solutions; experience in application and tissue science; and strong regulation to meet the express wishes and demanding situations of health care consumers.
About DuPont™ Liveo™ Healthcare Solutions DuPont™ Liveo™ is a generation leader identified globally by a wide variety of inventions in medical devices, biopharmaceutical remedies and pharmaceutical solutions. DuPont’s high-performance fabrics help create safer physical care environments and protect the fitness of fitnesscare patients and providers around the world. We help enable smarter fitnesscare and positive outcomes for patients. Learn more at liveo. dupont. com.
About DuPont Electronics
About DuPont DuPont (NYSE: DD) is a global leader in fabric innovation and generation responses that help industries and everyday life. Our employees apply a variety of science and expertise to help consumers advance their most productive concepts and deliver critical inventions in key markets such as electronics, transportation, construction, water, employee health and safety. For more data about the company, its activities and responses, scale up at http://www. dupont. com. Investors can access the data included in the Investor Relations segment of the online page in inverter. dupont. com.
Overview
On November 2, 2021, DuPont announced that it had entered into definitive agreements to obtain Rogers Corporation (“Rogers”) (the “Planned Acquisition of Rogers”). On January 25, 2022, Rogers shareholders approved the transaction. the term of the current quarter of 2022, subject to regulatory approvals and standard final conditions.
On February 18, 2022, DuPont had entered into definitive agreements to sell most of its Mobility segment.
The Company also announced on February 18, 2022 that its Board of Directors had approved the divestment of Delrin’s® acetal homopolymer (H-POM) business. In addition to entering into definitive agreements, the Company anticipates that the end of the delixture of Delrin® ® will be subject to regulatory approvals and other standard final situations (the “Delrin® Business Divestment” and, with the Divestment of M.
Cautionary Note On Forward-Looking Statements
This release comprises “forward-looking statements” within the meaning of the federal securities laws, adding Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In this context, submit appearance statements relate to long-term expected business and monetary functionality and monetary condition, and involve words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “search,” “see,” “fly,” “would,” “target,” and similar expressions and diversifications or negatives of those words.
Forward-looking statements address issues that are, to varying degrees, doubtful and subject to risks, doubts and assumptions, many of which are beyond DuPont’s control, that may cause actual effects to differ materially from those expressed in the forward-looking statements. forward-looking statements. Forward-looking statements are not promises of long-term effects. Some of the vital points that may cause DuPont’s actual effects to differ materially from those projected in such forward-looking statements include, but are not limited to: (i) the parties’ ability to meet expectations related to the timing, final touch and popularity and tax remedy of the sale of M
# # #
DuPont™, the DuPont oval logo, and all trademarks and service marks designated through ™Array SM or ® are assets of DuPont affiliates of Nemours, Inc. , unless otherwise noted.
31/05/22
Image:
High resolution: https://dupont. scene7. com/is/image/Dupont/Cooper River_high
Low resolution: https://dupont. scene7. com/is/image/Dupont/Cooper River_low
Proposed legend:
DuPont opens a new biopharmaceutical tube manufacturing facility with state-of-the-art infrastructure in Cooper River, USA. USA
Media Contact
Fiona Paul Pinter, DuPont, 41 5713084, fiona. paul-pinter@dupont. com
FUENTEDupont